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Use of Model Compounds to Study Potential Removal of Pharmaceuticals Using 
Octolig® 
 
Wen-shan Chang 
 
ABSTRACT 
 
 
 
The existence of pharmaceuticals in the environment has some adverse effects, and may 
pose threat to the organisms in the environment. The possibility of removing certain 
pharmaceuticals from wastewater was tested using Octolig®, a commercially available 
material with polyethyldiamine moieties covalently attached to high-surface area silica 
gel. Selected drug models were subjected to column chromatography in efforts to effect 
removal by means of ion encapsulation, the effectiveness of which would depend upon 
having appropriate anionic functional groups.   The experimental results suggested that 
the model compounds, Rose Bengal, Eosin Y, Erythrosine , ZPS, and Lissamine Green B 
were successfully encapsulated by Octolig®, while Methylene Blue with quaternary 
ammonium groups was (statistically) not. In contrast, complete success was attained for 
vi 
 
removing of each of three xanthenylbenzenes (Rose Bengal, Eosin Y, Erythrosine) that 
have both phenolic and carboxylic acid groups. In addition complete success was attained 
for ZPS (zinc phthalocyaninetetrasulfonate) with sulfonate groups present. A test of a real 
pharmaceutical compound, Amoxicillin, indicated that Octolig® can be used to remove 
this compound from aqueous media. 
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Introduction 
 
 
 
Background 
 
        With the rapid developing of human population, the demanding of pharmaceuticals 
also has increased exponentially.  However, without a proper disposal, drugs may 
contaminate our environment.  In recent years, the occurrence and fate of pharmaceutical 
substances in the environment have become an emerging issue in the world.  As a result, 
recent decades have seen increase attention being given to potential adverse effects from 
residues of pharmaceuticals. There has been a proliferation of research concerned with 
pharmaceuticals in the environment (Kümmerer, 2008). Regarding the potential adverse 
influences on wildlife and organisms, regulations associated with pharmaceuticals are 
relatively few in number. 
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Definition and the use of pharmaceuticals 
 
        Pharmaceutical drugs are defined as those organic or inorganic compounds used in 
the diagnosis, cure, mitigation, treatment, or prevention of disease (Buser et al, 1999). 
Pharmaceuticals are not only applied to humans’ usage, but the definition of 
pharmaceuticals can be extended to veterinary and plant pharmaceuticals, or even illicit 
drugs. What is more, pharmaceuticals are used in aquaculture, livestock farming, 
horticulture and bee keeping (Kümmerer, 2003). 
 
        Addition of pharmaceuticals to water directly can be done through usage in 
aquaculture, e.g., feeding and injecting (Stuart, 1983). There are more than 100 aquatic 
species cultured in the United State, but the development of the new pharmaceuticals 
which are used for aquatic diseases are scarce. There are only five FDA approved drugs 
available for aquaculture treatments (Gloyd, 1992). In general, the use of aquaculture 
pharmaceuticals for treating fish diseases or modulating fish growth is not sophisticated.  
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Occurrence in the environment 
 
        Many individual pharmaceuticals and their metabolites are found in the environment 
and the sewage plants. Many investigations show that pharmaceutically active 
compounds cannot be totally eliminated during wastewater treatment, and also can only 
be partially biodegraded in the environment (Daughton and Ternes, 1999; Heberer, 
2002).        
 
        The issue of persistent pharmaceutical compounds and residues is associated with 
the occurrence of pharmaceutical compounds in the environment. Many individual 
pharmaceutical compounds and metabolites have been found in the environment and the 
occurrence of pharmaceuticals has been investigated in many countries, including the 
E.U and the U.S. The improvements in analytical techniques are beneficial to the 
quantitative tracking of pharmaceuticals in queous environments. Several studies 
(Halling-Sorensen et al., 1998; Kümmerer, 2001; Heberer, 2002; Kolpin et al., 2002; 
Boyd et al., 2003) have noted that pharmaceuticals are present in wastewater treatment 
plant effluents, hospital wastewater effluents, surface water, ground water, and this will 
likely result in indirect human exposure to pharmaceuticals via drinking water supplies. 
A national survey released in 2002  reported that pharmaceuticals, hormones and other 
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organic pollutants were present in more than 80% of surface water streams tested (Kolpin 
et al., 2002).  In addition, as Heberer (2002) noted in his review, more than 80 
pharmaceutical active compounds have been detected in the µg/L range in the aquatic 
environment. 
 
       Because of the obvious effect on the environment, more data exist for antibiotics 
than other pharmaceuticals; what’s more, antibiotics are widely used for human 
medicine, veterinary medicine and agriculture. As a result, there are more obvious 
environmental issues involving antibiotics (Kümmerer, 2003). 
 
 
Pathways to the environment 
 
        There are many possible routes for pharmaceuticals to enter the environment. Most 
pharmaceuticals enter the environment through sewage treatment plants, agriculture run-
off, landfill leaching, or from direct application in the environment, as for example, the 
pharmaceuticals used in the aquaculture. Some pharmaceuticals pathways to environment 
had been summarized by Kümmerer (2008) who also described a similar pathway for 
antibiotics (Kümmerer, 2003).  
 
        Not only through direct disposal of unused pharmaceutical can chemicals enter our 
environment, but also the medications that are only partially biodegradable will go into 
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the environment through organism’s metabolicsystem. There are also large amounts of 
active pharmaceutical ingredients (APIs) that enter our environment by going down to the 
drains directly (Bound and Voulvoulis, 2005).  
 
 
Effects 
 
        Since pharmaceutical compounds are designed for medical usage, the lifetime of the 
chemicals should be long enough in order to do the therapeutic work. As a result, 
pharmaceutical compounds may persist in the environment (Jones et al., 2002). Although 
some drugs can be eliminated by human and animal’s metabolism or sewage systems, 
many researchers have pointed out that some pharmaceuticals cannot be completely 
eliminated by sewage treatment plants (Daughton and Ternes, 1999; Zwiener et al., 2000). 
Therefore, pharmaceuticals may remain in our environment, and pose threat to the 
organisms in our environment. As the result, pharmaceuticals are potentially toxic 
substances and may be defined as a new class of pollutants in the environment 
(Kümmerer, 2001).  
 
        Although the discharge of pharmaceutical could be present in low concentration, it 
may still cause significant effects, a hypothesis had been mentioned previously 
(Daughton and Ternes, 1999). It is that combination of low concentration 
pharmaceuticals and their transformation products through long-term accumulation may 
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have some ecologically-significant consequences. The others hypothesis is that the 
pharmaceuticals remaining in domestic water may have risks for human after lifetime 
ingestion.  
 
        One concern is that antimicrobials may affect, qualitatively or quantitatively, the 
resident microbial community in sediments (Nygaard et al, 1992). A second concern is 
that a certain class of pharmaceutical compounds like antibiotics may cause long-term 
change to bacteria, and make bacteria resistant. The resistant bacteria and, perhaps, 
multiple-resistant bacteria, may be involved in sewage, soil, or other environmental 
components. Such bacterial resistance has been detected in wastewater and in sewage-
treatment plants (Guardabassi et al, 1998; Witte, 1998). A third concern is that the 
pharmaceutical compounds, especially endocrine disrupting chemicals (EDCs), are 
suspected of causing harmful influences to the endocrine systems of human and animals 
(Ghijsen and Hoogenboezem, 2000).  
 
        In addition to active pharmaceuticals, their metabolites also need to be considered 
for their harmful effects. Pharmaceuticals may change during the digestion process by 
organisms and the additional molecules that are formed in the transformation process can 
cause pharmaceutical contamination, i.e., drug molecules may be altered by human and 
animals’ metabolism (Golan et al. 2007). Some drugs structures are largely changed by 
the microorganisms in the guts or by the enzymes in human’s metabolism before they are 
excreted. Therefore, their pharmaceutical properties are different to their parent drugs.  
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        Even though it is very possible that pharmaceuticals in the environments have 
adverse impacts, the risk of this issue is very hard to evaluate.  For many pharmaceutical 
compounds, their potential effects on organisms are not completely understood, 
especially when the pharmaceutical compounds co-exist in mixtures and form the so-
called chemical “cocktails” (Halling-Sorensen et al., 1998).  
 
 
Sources of pharmaceuticals 
 
        Even though there are several thousands APIs used as drugs in the world, there is 
inadequate data for usage for total pharmaceuticals. Drug production plants may also be 
making significant contribution to the total pharmaceutical concentration in the 
environment (Larsson et al, 2007). Amounts of pharmaceutical products are not 
manufactured evenly throughout the world.  In fact, production of pharmaceuticals is 
concentrated in five countries - USA, Japan, Germany, France and the UK, which are the 
most industrialized countries. Production in these five countries, represents two-thirds of 
all medicine produced.  In addition, 15% of the world’s population lives in high-income 
countries and use about 90% of total medicine, the use in USA accounts for over 52% of 
total medicinal consumption (World Health Organization, 2004). 
 
        Antibiotics are also used on a worldwide basis.  In 2000, 16,200 tons of antibiotics 
were produced in the United States, of which 70% was used for livestock (Union of 
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Concerned Scientists, 2001). European Federation of Animal Health (1999)  presented 
data that 13,288 tons of antibiotics were reportedly used in the EU (European Union) and 
Switzerland, of which 65% was for human medicine, 29% was used in the veterinary 
field and 6% was used as growth promoters. Besides, it was estimated the total antibiotic 
consumption was between 100,000 and 200,000 tons world-wide (Wise, 2002).   
 
     What’s more, 10 most prescribed medicines account for 12% of total usage of all 
medicine (World Health Organization, 2004). Pharmaceutical manufacturing processes 
involve in many series of steps, which can be taken in many different sites. Therefore, 
there is a risk that pharmaceuticals may enter the environment from many places during 
the production of APIs. However, according to Williams and Cook (2007), no studies 
have documented whether drug manufacturers could be main sources for pharmaceuticals 
in the environment. 
 
        Hospitals are one of the major contributors for the pharmaceuticals in the 
environments. In hospitals, pharmaceuticals are used for surgeries and other medical 
purposes, so hospitals could also be a concentrated source of waste pharmaceuticals, 
either through disposal of expired drugs, or through the metabolism of patients. For 
example, Ciprofloxcin was found in a German hospital effluent with a concentration of 
0.7-125 µg/L (Hartmann et al, 1999). Amoxicillin was found in another German hospital 
effluent with a concentration of 920-980 µg/L (Kümmerer, 2001). Considering that there 
were 203 hospitals in Florida alone in 2006 with around 2373 thousand patients served 
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per day (Bureau of the Census, 2008), there is an obvious need to develop methods to 
effect the removal of these agents. 
 
 
Assessment 
 
        Although pharmaceutical compounds in the environment have been considered a 
possible risk, the scientific investigations of the problems have not received much 
attention. In order to determine concentration of pharmaceuticals in aqueous sample, the 
assessments should be sensitive enough to reach as low as nanogram per liter level. 
Several assessments have been made by different analytical methods to determine the 
concentration of pharmaceuticals in biological samples, ex. blood and urine, and the 
detection limit can be lower to µg per liter (Ternes, 2001).   
 
        According to published research, high performance liquid chromatography (HPLC), 
gas chromatography with mass spectrometry (GC/MS) , gas chromatography  with 
tandem mass spectrometry (GC/MS2), liquid chromatography with mass spectrometry 
(LC/MS), liquid chromatography with tandem mass spectrometry (LC/MS2) (Hirsch, 
1998) have been used in pharmaceutical analyses.  
 
        Liquid chromatography with tandem mass spectrometry (LC/MS2) has become very 
popular and is commonly used in assessment methods used in pharmaceutical analysis 
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because of its high sensitivity and its ability to confirm compounds. This method can 
provide detailed information of drug’s chemical structure, and it is possible to separate 
and detect the pharmaceuticals that have the same molecular mass but different product 
ions (Díaz-Cruz and Barceló, 2005).  
 
 
Solutions to the problem 
 
        The possible solutions for reducing the adverse effects due to the presenting of 
pharmaceuticals in the environments could be differentiated into two categories or 
approaches. One is before the pharmaceutical compounds are discharged into the 
environment, preventing the unwanted pharmaceutical compounds enter the environment 
improperly. The other is reducing of the amounts of pharmaceuticals compounds already 
existing in the environment. 
 
        In order to prevent pharmaceuticals from entering the environment improperly, an 
acceptable solution could be reduction of the amounts of pharmaceuticals discharged into 
the environment. Proper drug disposal is an emerging environmental issue. The 
previously recommended disposal methods for unused drugs were dumping in the toilet 
or sink. By doing this, children are protected from accidental poisoning in the home. 
However, improper disposals may have adverse impacts on our environment and human 
health. Since the modern sewage systems are not designed to deal with unused 
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pharmaceuticals, it is not proper to flush them down the toilets or pour them down to the 
sinks. Throwing unwanted medicines to the trash is also unacceptable. Pharmaceuticals 
also have the potential to leach out from the landfill. Therefore, returning unwanted 
medicines to pharmacies or hospitals may be good environmental-friendly options, but 
since they may not want them, then approved source of incineration could be a better 
option. 
 
        Another potential method for preventing waste pharmaceuticals enter the 
environment is creating additional waste stream for health care organizations (Smith, 
2009). Since health care organizations, such as hospitals, are one of the main sources of 
pharmaceutical passage to the environment, developing safe and effective pharmaceutical 
waste management streams can reduce the amount of pharmaceuticals that go into the 
environments. 
 
        Recycling can also reduce the pharmaceutical waste amount in the environment. The 
unwanted but potentially usable drugs can be returned to the manufacturer through 
hospitals or pharmacies. By doing this, unwanted pharmaceuticals are not treated as 
wastes, and disposed to our environment. In addition, recycling unwanted drugs can ease 
the burden of waste disposal, and unwanted drugs have the potential to be reused.  
 
        Besides the aforementioned three solutions for preventing the pharmaceutical 
compounds from entering the environment improperly, a lot of researchers are putting 
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efforts on removing the pharmaceutical compounds already in the environment. For 
examples, there is an increasing interest on the use of advanced oxidation processes 
(AOPs) for the removal of pharmaceuticals residues from municipal wastewater 
treatment plant effluents in recent year (Comninellis et al, 2008). APOs are a set of 
treatments that can remove organic and inorganic compounds by oxidation. This 
technique is based on the intermediacy of high reactive chemicals such as hydroxyl 
radicals to destruct the target compounds. Different reagents oxidize the compounds 
intend to be removed. The most common used reagent is Fenton's reagent because it is 
simple and high-efficient in organic compounds’ removal (Faouzi et al, 2006). 
 
 
Statement of the problem 
 
        More than 80 active pharmaceutical ingredients from various therapeutic usages, 
such as antibiotics, analgesics and hormones have been detected in the aquatic 
environment (Heberer, 2002; Daughton and Ternes, 1999), and these ingredients affect 
human health through drinking water or aquatic recreational activities. There are 
numerous negative effects due to environmental existence of pharmaceutical compounds. 
 
        Most of active pharmaceutical ingredients enter organisms through the pathways in 
the aquatic environment. In order to eliminate the pharmaceuticals compounds, finding 
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an effective way to probe entry of the pharmaceuticals into aquatic environment could be 
useful. 
 
 
Plan of attack 
 
        While considerable attention has been paid to research issues related to removing the 
pharmaceuticals in the environment, simple and cost-efficient methods still need to be 
developed for removing pharmaceuticals. A previous study indicated that Octolig®, a 
polyethylenediamine covalently attached to a high-surface-area silica gel, is capable of 
removing such anions as phosphate, sulfate, nitrate, and nitrite in a aquatic environment, 
presumably through a process of encapsulation by the protonated polyethylenediamine 
groups (Stull and Martin, 2009).  A possible mechanism of anion encapsulation by 
Octolig is shown in Fig. 1. The anions were presumed to be associated with “arms” of 
polyethylenediamine where there are positive charges on the surface of stationary phase 
(silica gel of Octolig®). The purpose of this research was to ascertain the potential 
possibility of using Octolig® to remove pharmaceuticals before or after reaching an 
aquatic environment. 
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Fig. 1. Possible structure of encapsulation of anions (An-) by Octolig® showing a one-
arm model (Stull and Martin, 2009). 
 
 
        Octolig® has the advantages of simplicities, stabilities, re-generation and 
comparative low cost ($40/kg wholesale). Using Octolig® to remove the pharmaceutical 
compounds may be simple, and easy to operate than other treatment processes. Octolig® 
has enormous stability coefficients, and is also stable in pH ranges from 0.5 to 10.5 and at 
temperatures from 0°C to 80°C. Besides, Octolig® can be regenerated by a small volume 
of dilute acid hundreds of times without losing its capacity (Metre-General, Inc, 2009). 
 
        It is proposed that certain pharmaceuticals could be removed through 
chromatography using a commercially available product called Octolig®. The purpose of 
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this research is to investigate if Octolig® has the potential to remove pharmaceutical 
compounds from the aquatic environment.  To evaluate this possibility, this research will 
focus on testing model compounds in terms of available functional groups.  Experiments 
with model compounds could serve as the basis for a study of real pharmaceuticals, and 
the practicality of the proposed method of removing pharmaceutical compounds could be 
demonstrated through a real pharmaceutical compound study. 
 
 
Experimental methods 
 
        In order to deepen our understanding of how pharmaceuticals can be removed by 
Octolig®, the present study examines whether Octolig® might be suitable for removing 
pharmaceuticals from different aqueous matrix by using model compounds.  The working 
hypothesis is that certain pharmaceuticals might have appropriate functional groups to 
enable appropriate encapsulation by Octolig®. 
 
        A chromatography procedure was developed for the examination, and a series of 
model compounds were chosen. The primary criterion for selecting model compounds 
was that they have the functional group(s) and they are easy to observe visually during 
chromatography. After testing model compounds, a pharmaceutical compound, 
Amoxicillin, was chosen to test the practical application to a real pharmaceutical 
compound. 
16 
 
 
 
 
Materials and Methods 
 
 
 
Source of reagents and materials 
 
        Octolig® (CAS Registry Number 404899-06-5), a polyethylenediamine covalently 
attached to a high-surface area silica gel with a density of 0.455 g/cm3, was a gift from 
Metre-General, Inc., Frederick, Co. The structure of Octolig® is presented in Fig. 2. 
Methylene blue was obtained from EMD Chemicals Inc. Rose Bengal was obtained from 
J.T.Baker Chemical Co. Eosin Y was obtained from Sigma-Aldrich Chemical Co., and 
Erythrosine was acquired from J. Preston LTD. ZPS was a gift from Procter and Gamble.  
Lissamine Green B was purchased from Acros Organics Co and Amoxicillin was from 
Sigma-Aldrich Chemical Co. Well water samples were obtained from a private well at 
3402 Valencia Road in Original Carrollwood, Tampa, FL. Prior to use; in order to 
remove undissolved solids, the water was filtered through a 3- µ Millipore membrane 
filter using an all-glass apparatus. 
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Fig. 2. Chemical structure of Octolig®. 
 
 
Analytical methods 
 
        Measurements of total dissolved solids (TDS) of aqueous samples were done by a 
Fisher Scientific digital conductivity meter, and the pH values were obtained by an Orion 
model 290A pH/ISE meter connected with an Orion pH triode electrode (modal 9107BN). 
The concentrations of solutions were acquired from the absorbance measurements using a 
Shimadzu UV-2401 PC UV/Vis recording spectrophotometer.  Data were collected, and 
spectra were saved to a disk using OriginPro 8.0 for further use. 
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Chromatography experiments 
 
        The chromatography process was similar as Octolig used before (Martin et al, 
2008).  The chromatography procedure was as follows. The Octolig was used as 
received with a pretreatment by suspending the solid in DI water then decanting the water 
to remove the fines. A CHEMGLASS column, 2cm (id) equipped with a glass frit and a 
Teflon stopcock, was packed with Octolig, and washed with about 1L of appropriate 
solvent, i.e. DI (deionized) water, tap water and well water were used as different 
matrices.  Aqueous samples were chromatographed using a rate of 10mL/min using a 
Spectra/chron™ peristaltic pump. A series of 50-mL fractions were collected, and 
measured by conductivity meter, pH meter and UV-VIS absorbance meter. The average 
concentrations of the effluents were compared with the input concentrations, and the 
percentage removal was calculated and recorded. 
 
 
Molar extinction coefficient measurements 
 
        Serial dilutions for each model compound were prepared from a known stock 
solution. Absorbance values were recorded for a wavelength near the λmax for each 
dilution using a Shimadzu UV-2401 PC spectrophotometer.  Concentrations were 
19 
 
prepared to ensure that absorbance values did not exceed OD=1.5.  Molar extinction 
coefficients were determined using the Beer-Lambert law, in which the slope of the 
absorbance versus concentration plot is equal to the extinction coefficient times the path 
length, in which the path length was 1.0 cm.   The data analysis used EXCEL software 
and the molar extinction coefficients could be obtained from the linear equations.  
 
        Measured wavelengths and absorbance for each model compounds are shown in 
Table 1. Molar extinction coefficient of Rose Bengal, which is 57,886M-1cm-1 at 544nm, 
was acquired as the slope value in the trend line. The molar extinction coefficients of  
Eosin Y, Erythrosine and other dyes were acquired by the same procedures (Table 1).  
 
 
Table 1. Molar extinction coefficients and measured wavelength of model compounds. 
Dye λmax, nm εmax 
Methylene blue 662 73004 
Rose Bengal 544 57886 
Eosin Y 516 71976 
Erythrosine 526 71235 
ZPS 668 23279 
Lissamine Green B 635 91891 
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Test for fluorescence 
 
        A sample of Amoxicillin and all model compounds were tested using light from a 
Model UVL-56 Blak-Ray® Lamp, i.e., long wave UV 366nm obtained from Ultraviolet 
Products, Inc San Gabriel, CA. No compound showed fluorescence by using Blak-Ray® 
Lamp in a darken laboratory. 
 
 
Application to Amoxicillin 
 
        After testing model compounds, Amoxicillin was chosen to be tested for the 
possibility of this technique to be applied on real pharmaceutical compounds. The 
extinction coefficient of Amoxicillin was measured, and acquired as 1040cm-1M-1 at 275 
nm. The procedure was the same as previous procedure for model compounds. 
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Results and Discussion 
 
 
 
Compound selection 
 
        The number of criteria can characterize a pharmaceutical – popularity is one. The 
top five most prescribed drugs in 2008(Towner, 2009) were Hydrocodone , Lisinopril, 
Simvastatin, Levothyroxine, and Amoxicillin. CAS numbers, therapeutic usages, and 
chemical formula are shown in Table 2. Structural features may also characterize 
pharmaceuticals and the simplest way is by functional groups. Accordingly, Lisinopril, 
Levothyroxine and Amoxicillin have either carboxyl (all three) or phenolic groups (last 
two) or both (last two). Amino groups could also be of interest, and these are found in 
Lisinopril, Levothyroxine and Amoxicillin. The structures of these pharmaceuticals are 
shown in Fig. 3. 
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Fig. 3. Structures of the top 5 most prescribed pharmaceuticals in 2008 (Towner, 2009). 
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Table 2. The compound names, CAS numbers, therapeutic uses and chemical formulas 
of the top five most prescribed pharmaceuticals in 2008(Jones et al, 2002; Towner, 2009). 
Compound 
Name 
CAS Number Therapeutic Use Chemical 
Formula 
Hydrocodone 125-29-1 Analgesic C18H21NO3  
Lisinopril 83915-83-7 Analgesic C21H31N3O5 
Simvastatin 79902-63-9 lipid-lowering drug C25H38O5  
Levothyroxine 51-48-9 Hormone replacement C15H11I4NO4  
Amoxicillin 26787-78-0 Antibiotic C16H19N3O5S  
 
         In considering the functional groups, the model compounds were selected for the 
evaluation of the potential of pharmaceuticals to be encapsulated by Octolig.  A series 
of model compounds, which are Methylene blue, Rose Bengal, Eosin Y, Erythrosine, 
ZPS, and Lissamine Green B were selected for testing. There experimental results may 
lead to a better understanding of the possibility of removing the pharmaceuticals in 
aquatic environment by Octolig.  
 
        Lissamine Green B is one of the common dyes and had been reported to be removed 
by one of the APOs process-Electro-Fenton oxidation (Rosales, 2009). Amoxicillin is a 
widely used antibiotic, and had been documented to be present in Sewage Treatment 
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plants (STPs) effluents. Concentrations of Amoxicillin up to 120 ngL-1 have been 
reported in STP effluents in Italy (Andreozzi, 2005). Because of having the functional 
groups, carboxyl and amino, that have the potential to be encapsulated by Octolig®, 
Amoxicillin was chosen for experimental test. Presumably carboxyl groups would be 
favorable for removal; amino groups would not be. Also it was commercially available 
for a reasonable price. Lisinopril was commercially available, but not at a reasonable 
price. 
 
 
Medical uses 
 
        Methylene blue, a guanylate cyclase inhibitor is used to treat vasoplegia which is a 
frequent complication after cardiopulmonary bypass (Leyh, 2003). Rose Bengal (4, 5, 6, 
7-tetrachloro-20, 40, 50, 70-tetraiodofluorescein disodium, or RB) is a water-soluble 
photo-sensitizer with a high molar extinction coefficient in the red region of the 
spectrum, and Provecuts Pharmaceuticals discovered about a decade ago that Rose 
Bengal can kill cancer cells, but not normal cells; besides, it was found that Rose Bengal 
can be used as a treatment for metastatic melanoma (Thompson et al, 2008). PV-10 is ten 
percent (w/v) Rose Bengal in saline, and PV-10 treatment for melanoma is safe and 
tolerated for patients. Unfortunately, Food & Drug Administration has not approved it as 
a medical treatment. Since Rose Bengal is not patentable, no pharmaceutical company 
can make much profit by producing it (McDuffie, 2009).  
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Aggregation 
 
        While doing the experiment, it was found that there are undissolved solids in Rose 
Bengal solutions when concentration is high. When Rose Bengal is in aqueous solution at 
a concentration of 2.5×10-5M, Rose Bengal is present as its monomer (Fini et al, 2007). 
The aggregation of Rose Bengal impacts on the photochemical response, such as 
absorbance at high concentration (Daraio and San Romàn, 2001). In order to prevent the 
aggregation of Rose Bengal that impacts the absorbance when measuring the sample by 
UV-VIS, the sample containers were covered by aluminum foil, and the samples were 
prepared with concentrations lower than 2.5×10-5M. 
 
 
Experiment results 
 
        A series of model compounds were selected for testing their potential for 
encapsulation by Octolig®. Methylene blue, for example, has a pair of tertiary amino 
groups. Fluorescein and the halogenated derivatives are substituted xanthenylbenzenes 
that have both phenolic groups and carboxylic acid groups.  The series includes Rose 
Bengal, Eosin Y, Erythrosine, and sodium fluorescein. The structures of model 
compounds are shown in Fig. 4. After chromatography process, the percentage removed 
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of each model compounds were obtained, and experimental results are show in Table 3, 
and more detailed data are presented in the Appendices. 
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Fig. 4. Structures of model compounds. 
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Table 3. Passage of aqueous sample over a chromatographic column packed with 
Octolig® at a flow rate of 10 mL/min (50-mL aliquots were collected). 
Dye,       
(Matrix) Batch§ Fraction TDS(ppm) pH Concentration* %Removed 
Methylene blue†       
(DI water) No. 1 Stock 2 7.34 3.321 --- 
  4-15 1.9±0.2 6.09±0.24 3.318±0.11 1.92±2.57 
 No. 1 Stock 3 7.61 0.876 --- 
  4-9 4.0±0 6.33±0.22 0.844±0.02 3.72±2.71 
 No. 1 Stock 7 5.56 2.429 --- 
  4-10 5.2±0.4 5.82±0.26 2.550±0.06 0.00±0.00 
Rose Bengal†       
(DI water) No. 1 Stock 3 6.09 4.170 --- 
  4-9 6.5±0.55 5.63±0.35 0.949±0.266 77.3±6.4 
 No. 1 Stock 4 6.58 1.042 --- 
  4-9 5.0±0 5.78±0.10 0.008±0.071 99.2±0.7 
 No. 1 Stock 4 7.05 9.600 --- 
  4-10 5.0±0 6.65±0.24 0.045±0.022 99.5±0.2 
 No. 2 Stock 4 7.18 9.647 --- 
  4-10 5.0±0 6.34±0.35 0.070±0.010 99.3±0.1 
(Well water) No. 2 Stock 159 7.93 21.921 --- 
  6-10 220.3±3.87 6.74±0.07 0.012±0.011 99.9±0.0 
Eosin Y†       
(DI water) No. 1 Stock 9 6.27 55.185 --- 
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  4-10 14.0±0.0 6.24±0.08 0.713±0.009 87.1±0.2 
 No. 1 Stock 10 6.68 56.213 --- 
  4-10 20.0±0.0 5.99±0.08 0.002±0.005 100.0±0.2 
 No. 1 Stock 10 6.72 86.290 --- 
  4-10 13.0±0.5 5.98±0.08 0.035±0.031 100.0±0.0 
 No. 2 Stock 10 6.83 90.044 --- 
  4-10 15.2±0.3 5.88±0.04 0.927±0.065 99.0±0.1 
(Well water) No. 2 Stock 164 7.97 85.167 --- 
  6-10 205.3±1.3 6.70±0.09 0.054±0.037 99.9±0.0 
Erythrosine†       
(DI water) No. 1 Stock 30 7.48 59.662 --- 
  4-10 31.1±0.8 6.71±0.06 0.642±0.027 98.9±0.0 
 No. 1 Stock 32 9.54 73.14 --- 
  4-10 34.9±0.3 6.22±0.13 0.094±0.020 99.9±0.0 
 No. 2 Stock 28 8.66 78.753 --- 
  4-10 31.9±0.3 6.13±0.10 0.046±0.027 99.9±0.0 
(Tap water) No. 2 Stock 293 7.76 94.897 --- 
  4-10 352.7±7.5 7.45±0.08 0.122±0.019 99.9±0.0 
(Well water) No. 2 Stock 203 8.33 105.566 --- 
  4-10 199.9±1.2 8.42±0.06 1.504±0.070 98.6±0.1 
ZPS†       
(DI water) No. 1 Stock 16 6.99 126.29 --- 
  4-10 23.3±3.7 6.79±0.16 3.860±0.159 96.9±0.1 
 No. 2 Stock 17 7.80 22.77 --- 
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  4-10 19.4±0.9 6.45±0.30 0.264±0.034 98.8±0.2 
(Well water) No. 2 Stock 183 7.54 4.081 --- 
  4-10 234.1±3.9 7.09±0.16 0.000±0.000 100.0±0.0 
 No. 2 Stock 175 8.34 67.335 --- 
  4-10 342.6±3.1 7.17±0.05 2.730±0.090 95.9±0.4 
(DI water) No. 2 Stock 16 6.48 57.219 --- 
  4-10 18.3±0.8 6.43±0.05 1.424±0.145 97.5±0.0 
Lissamine Green B‡ 
(DI water) No. 1 Stock 9 6.27 9.087 --- 
  4-10 8.1±0.3 6.20±0.10 0.017±0.005 99.8±0.1 
 No. 1 Stock 10 6.24 9.294 --- 
  4-10 6.9±0.4 6.10±0.13 0.008±0.005 99.9±0.1 
(Well water) No. 2 Stock 169 8.09 7.636 --- 
  4-10 211±6 6.64±0.14 0.005±0.001 99.9±0.0 
 No. 2 Stock 174 7.92 7.542 --- 
  4-10 213±5 6.64±0.10 0.002±0.002 100±0.0 
 No. 2 Stock 175 7.88 0.74 --- 
  4-10 216±4 6.92±0.01 0.002±0.001 99.7±0.1 
* Concentration unit is 10-6 M.  
† A 2.0-cm id id chromatographic column was used, and the total volume of Octolig® 
   used was 69mL3. 
‡ A 3.0-cm id chromatographic column was used, and the total volume of Octolig® used 
   was 127mL3. 
§ Octolig® was obtained in two different batches from Metre-General, Inc. 
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        In order to test the possibility of application on real pharmaceutical compound, a real 
pharmaceutical compound, Amoxicillin, was chosen, and tested by the same 
chromatography procedure. After chromatography process, the percentage removed of 
Amoxicillin was obtained, and experimental results are shown in Table 4, and more 
detailed data are presented in the Appendices. 
 
 
Table 4. Passage of aqueous Amoxicillin sample over a 3.0-cm id chromatographic 
column packed with 18cm of Octolig® at a flow rate of 10 mL/min (50-mL aliquots were 
collected). 
Matrix Fraction TDS, ppm pH Concentration, 106M %Removed 
DI water Stock 4 6.17 839.269 --- 
 4-10 6±0 7.01±0.18 4.945±3.653 99.4±0.4 
Stock 3 6.19 1229.808 --- 
 4-10 6±1 6.83±0.07 2.885±3.092 99.8±0.3 
Stock 5 5.97 741.346 --- 
 4-10 2±1 5.59±0.10 17.170±9.594 98.8±0.6 
Well water Stock 119 6.56 750.000 --- 
 4-10 176±14 6.48±0.06 11.676±0.012 99.2±0.4 
Stock 153 7.12 912.500 --- 
 4-10 193±24 6.72±0.06 57.418±22.258 96.9±1.2 
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Conclusions 
 
        The experimental results show Octolig® could effectively remove model 
compounds with proper anionic functional groups. For example, removal of Methylene 
blue with quaternary ammonium groups and one phenolic group was less than 2% 
averaged over three trials (Table 3) and within experimental error was a complete failure. 
In contrast, model compounds, Rose Bengal, Eosin Y, Erythrosine, ZPS and Lissamine 
Green B, were successfully encapsulated by Octolig®. Rose Bengal, Eosin Y, 
Erythrosine, which have both phenolic and carboxylic acid groups, were removed 
quantitatively by Octolig® in aquatic environment. In addition, complete success was 
attained for ZPS and Lissamine Green B with sulfonate anions present.  
 
                Matrix effects were studied using three different water sources – DI water, tap 
water, and well water from Floridian Aquifer.  For example, the Trial 3 and Trial 4 of 
Erythrosine with different matrixes (DI water and tap water) showed the same percentage 
removals (99.9%). Besides, the data indicate the removal ability of Octolig® did not 
depend on different batches. For example, as the data shows (Table 3), the stock 
concentrations were similar for Trial 3 (9.600×10-6M) and Trial 4 (9.647×10-6M) of Rose 
Bengal tests, and the percentage removals were also similar (99.2% and 99.5%) while 
using  two different batches of Octolig®. The results of Student’s T-test showed no 
34 
 
significant different between the two data groups from different batches of Octolig® 
(P=0.146).  
 
        While encapsulating compounds with phenolic and carboxylic acid groups, no 
significant correlation was discerned between pH values and removal ability of Octolig® 
for Erythrosine for a pH value above 7, just as was observed for Rose Bengal and Eosin 
Y. For example, the Trial 3, 4, and 5 of Erythrosine with different pH values (9.54, 8.66 
and 7.76) showed the same percentage removals (99.9%). Figure 7 also shows no obvious 
pH effects on removal of Erythrosine, presumably because the pH value was above that 
need for removal of a carboxylic proton. These three fluorescein dyes have pKa values 
around 5 (Levitanf, 1977;Mchedlov-Petrosyan et al, 2006 ), and when the pH value above 
7, the ionization of the proton on carboxylic acid functional group is more the 99%.  
 
        However, when pH was lower than about 6.5, the removal ability of Octolig® for 
Rose Bengal and Eosin Y was not good enough. By increasing the pH value, Octolig® 
removed a greater percentage of xanthenylbenzene. Figure 5 shows the fact that 
percentage removal can be increased from 77.3% to 99.2% when pH over 6.58. There is 
also obvious pH effect on removal of Eosin Y (Fig. 6). For example, the percentage 
removal of Eosin Y sample with the pH of 6.27 was 87.1%, but with a pH value greater 
than 6.68, the percentage removal could be increased to over 99%.   
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Fig. 5. pH effect on percentage removal of Rose Bengal. 
 
 
 
Fig. 6.  pH effect on percentage removal of Eosin Y. 
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Fig. 7. pH effect on percentage removal of Erythrosine. 
 
 
        In adddtion, while encapsulating compounds with sulfonate anions groups, there was 
no significant relationship between pH values and removal ability of Octolig®, e.g., for 
ZPS and Lissamine Green B. For example, the percentage removals did not increase with 
higher pH values in Trial 2 and 3of ZPS. The pH values are 7.54 in Trial 3 and 7.80 in 
Trial 2, but the percentage removals are 100% for Trial 3 and 98.8% for Trial 2.  Figures 
8 and 9 also show there is no obvious relationship between pH and percentage removal of 
ZPS and Lissamine Green B. 
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Fig. 8. pH effect on percentage removal of ZPS. 
 
 
Fig. 9. pH effect on percentage removal of Lissamine Green B. 
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        Octolig® not only has the potential to remove simple anions, such as phosphate, 
sulfate, nitrate, and nitrite from water, but also has the potential to remove dyes and those 
pharmaceutical compounds with suitable functional groups in an aquatic environment at 
low concentration. Selected drug models compounds were subjected to column 
chromatography in efforts to effect removal by means of ion encapsulation, the 
effectiveness of which would depend upon having appropriate anionic functional groups.   
 
        The experimental results demonstrated that Methylene Blue with quaternary 
ammonium groups could not be removed successfully. In contrast, complete success was 
attained for removal of each of three xanthenylbenzenes (Rose Bengal, Eosin Y, and 
Erythrosine) that have both phenolic and carboxylic acid groups.  In addition complete 
success was attained for ZPS (zinc phthalocyaninetetrasulfonate) and Lissamine Green B 
with sulfonate anions present. The real pharmaceutical compound, Amoxicillin, with 
carboxyl group can be removed by Octolog® successfully. Overall, The pharmaceutical 
compounds which have phenol, carboxylic acid and sulfonate functional groups have the 
potential to be removed by Octolig®.  
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Appendices A: Experimental data for model compounds 
 
 
 
Table A.  Passage of  Methylene blue solution sample with pH adjustment over a 2-cm id chromatographic 
column packed with 25cm of Octolig® at a flow rate of 10 mL/min (50-mL aliquots were collected). 
Trial Matrix Batch Fraction TDS, ppm pH Concentration, 
106M 
%Removal 
Stock 2 7.34 3.321 --- 
1 DI water 1 4-15 1.9±0.2 6.09±0.24 3.318±0.11 1.92±2.57 
Stock 3 7.61 0.876 --- 
2 DI water 1 4-9 4.0±0 6.33±0.22 0.844±0.02 3.72±2.71 
Stock 7 5.56 2.429 --- 
3 DI water 1 4-10 5.2±0.4 5.82±0.26 2.550±0.06 0.00±0.00 
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Table A-1.  Passage of  Methylene blue aqueous sample with pH adjustment over a 2-cm id 
chromatographic column packed with 25cm of Octolig® at a flow rate of 10 mL/min (50-mL aliquots were 
collected). 
Fraction No. TDS, ppm pH Concentration, 106M Absorbance 
1 2 7.45 0.558 0.041 
2 2 7.13 0.844 0.062 
3 2 6.77 2.498 0.182 
4 2 6.70 2.874 0.210 
5 2 6.54 3.109 0.227 
6 2 6.51 3.249 0.237 
7 2 6.44 3.287 0.240 
8 2 6.07 3.343 0.244 
9 2 5.73 3.360 0.245 
10 2 5.75 3.362 0.245 
11 2 6.18 3.421 0.250 
12 2 5.97 3.443 0.251 
13 2 5.87 3.462 0.253 
14 2 5.82 3.457 0.252 
15 1 5.54 3.454 0.252 
Sample 2 7.34 3.321 0.242 
 
Average Concentration= 3.318 ×10-6M 
Standard Deviation= 0.175 
%Removal= 1.92±2.57 
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Table A-2. Passage of  Methylene blue aqueous sample with pH adjustment over a 2-cm id 
chromatographic column packed with 25cm of Octolig® with NaOH pre-rinsed at a flow rate of 10 mL/min 
(50-mL aliquots were collected). 
 
Fraction No. TDS, ppm pH Concentration, 106M Absorbance 
1 3 6.61 0.511 0.037 
2 2 6.45 0.535 0.039 
3 4 6.67 0.740 0.054 
4 4 6.45 0.806 0.059 
5 4 6.27 0.829 0.061 
6 4 6.66 0.841 0.061 
7 4 6.35 0.853 0.062 
8 4 6.21 0.864 0.063 
9 4 6.03 0.870 0.064 
Sample 3 7.61 0.876 0.064 
 
Average Concentration= 0.844 ×10-6M 
Standard Deviation= 0.237 
%Removal= 3.72±2.71 
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Table A-3.  Passage of  Methylene blue aqueous sample over a 2-cm id chromatographic column packed 
with 25cm of Cuprilig® at a flow rate of 10 mL/min (50-mL aliquots were collected). 
 
Fraction No. TDS, ppm pH Concentration, 106M Absorbance 
1 8 6.35 0.604 0.044 
2 7 5.87 1.780 0.130 
3 8 5.70 2.319 0.169 
4 6 6.12 2.453 0.179 
5 5 6.18 2.513 0.183 
6 5 5.73 2.583 0.189 
7 5 5.66 2.558 0.187 
8 5 5.53 2.608 0.190 
9 5 5.71 2.593 0.189 
Sample 7 5.56 2.429 0.177 
 
Average Concentration= 2.551 ×10-6M 
Standard Deviation= 0.059 
%Removal= 0.00±0.00 
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Table B.  Passage of  aqueous Rose Bengal sample over a 2-cm id chromatographic column packed with 
25cm of Octolig® in Batch 1 at a flow rate of 10 mL/min (50-mL aliquots were collected). 
 
Trial Matrix Batch Fraction TDS, ppm pH Concentration, 
106M 
%Removal 
Stock 3 6.09 4.170 --- 
1 DI water 1 4-9 6.5±0.55 5.63±0.35 0.949±0.266 77.3±6.4 
Stock 4 6.58 1.042 --- 
2 DI water 1 4-9 5.0±0 5.78±0.10 0.008±0.071 99.2±0.7 
Stock 4 7.05 9.600 --- 
3 DI water 2 4-10 5.0±0 6.65±0.24 0.045±0.022 99.5±0.2 
Stock 4 7.18 9.647 --- 
4 DI water 2 4-10 5.0±0 6.34±0.35 0.070±0.010 99.3±0.1 
Stock 159 7.93 21.921 --- 
5 
Well 
water 2 6-10 220.3±3.87 6.74±0.07 0.012±0.011 99.9±0.0 
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Table B-1.  Passage of  Rose Bengal aqueous sample over a 2-cm id chromatographic column packed with 
25cm of Octolig® in Batch 1 at a flow rate of 10 mL/min (50-mL aliquots were collected). 
 
Fraction No. TDS, ppm pH Concentration, 106M Absorbance 
1 14 6.84 0.567 0.033 
2 12 5.88 0.608 0.035 
3 10 6.41 0.709 0.041 
4 7 6.12 0.799 0.046 
5 7 5.58 1.305 0.076 
6 7 5.11 1.278 0.074 
7 6 5.59 0.754 0.044 
8 6 5.51 0.761 0.044 
9 6 5.89 0.794 0.046 
Sample 3 6.09 4.170 0.241 
 
 Average Concentration= 0.949 ×10-6M 
Standard Deviation= 0.266 
%Removal= 77.3±6.4 
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Table B-2.  Passage of  Rose Bengal aqueous sample with pH adjustion with NaOH over a 2-cm id 
chromatographic column packed with 25cm of Octolig® in Batch 1  at a flow rate of 10 mL/min (50-mL 
aliquots were collected). 
 
Fraction No. TDS, ppm pH Concentration, 106M Absorbance 
1 8 5.34 0.003 0.000 
2 6 5.82 0.016 0.001 
3 6 5.79 0.023 0.001 
4 5 5.90 0.011 0.001 
5 5 5.88 0.021 0.001 
6 5 5.80 0.008 0.000 
7 5 5.69 0.001 0.000 
8 5 5.66 0.003 0.000 
9 5 5.74 0.005 0.000 
Sample 4 6.58 1.042 0.060 
 
Average Concentration= 0.008 ×10-6M 
Standard Deviation= 0.007 
%Removal= 99.2±0.7 
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Table B-3.  Passage of  Rose Bengal aqueous sample with pH adjustion with NaOH over a 2-cm id 
chromatographic column packed with 25cm of Octolig® in Batch 2 at a flow rate of 10 mL/min (50-mL 
aliquots were collected). 
 
Fraction No. TDS, ppm pH Concentration, 106M Absorbance 
1 9 7.78 0.002 0.000 
2 8 7.56 0.050 0.003 
3 6 7.34 0.022 0.001 
4 5 7.14 0.065 0.004 
5 5 6.80 0.035 0.002 
6 5 6.71 0.065 0.004 
7 5 6.59 0.043 0.002 
8 5 6.55 0.070 0.004 
9 5 6.46 0.035 0.002 
10 5 6.31 0.000 0.000 
Sample 4 7.05 9.600 0.556 
 
Average Concentration= 0.045 ×10-6M 
Standard Deviation= 0.025 
%Removal= 99.5±0.0 
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Table B-4.  Passage of  Rose Bengal aqueous sample with pH adjustion with NaOH over a 2-cm id 
chromatographic column packed with 25cm of Octolig® in Batch 2 at a flow rate of 10 mL/min (50-mL 
aliquots were collected). 
 
Fraction No. TDS, ppm pH Concentration, 106M Absorbance 
1 8 7.49 0.000 0.000 
2 7 7.34 0.000 0.000 
3 6 7.16 0.064 0.004 
4 5 6.82 0.076 0.004 
5 5 6.67 0.073 0.004 
6 5 6.65 0.091 0.005 
7 5 6.34 0.067 0.004 
8 5 6.06 0.061 0.004 
9 5 5.98 0.062 0.004 
10 5 5.83 0.060 0.003 
Sample 4 7.18 9.647 0.558 
 
Average Concentration= 0.070 ×10-6M 
Standard Deviation= 0.011 
%Removal= 99.3±0.1 
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Table B-5.  Passage of  Rose Bengal aqueous sample in well water with pH adjustion with NaOH over a 2-
cm id chromatographic column packed with 25cm of Octolig® in Batch 2 at a flow rate of 10 mL/min 
(50mL aliquots were collected). 
 
Fraction No. TDS, ppm pH Concentration, 106M Absorbance 
1 5 6.76 0.000 0.000 
2 35 6.25 0.023 0.001 
3 176 6.56 0.033 0.002 
4 213 6.63 0.035 0.002 
5 215 6.65 0.006 0.000 
6 222 6.72 0.017 0.001 
7 223 6.75 0.000 0.000 
8 223 6.78 0.016 0.001 
9 223 6.81 0.004 0.000 
10 223 6.83 0.006 0.000 
Sample 159 7.93 21.921 1.269 
 
Average Concentration= 0.012 ×10-6M 
Standard Deviation= 0.012 
%Removal= 99.9±0.0 
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Table C.  Passage of  aqueous Eosin Y sample over a 2-cm id chromatographic column packed with 25cm 
of Octolig® at a flow rate of 10 mL/min (50-mL aliquots were collected). 
 
Trial Matrix Batch Fraction TDS, ppm pH Concentration, 
106M 
%Removal 
Stock 9 6.27 55.185 --- 
1 DI water 1 4-10 14.0±0.0 6.24±0.08 0.713±0.009 87.1±0.2 
Stock 10 6.68 56.213 --- 
2 DI water 1 4-10 20.0±0.0 5.99±0.08 0.002±0.005 100.0±0.2 
Stock 10 6.72 86.290 --- 
3 DI water 1 4-10 13.0±0.5 5.98±0.08 0.035±0.031 100.0±0.0 
Stock 10 6.83 90.044 --- 
4 DI water 2 4-10 15.2±0.3 5.88±0.04 0.927±0.065 99.0±0.1 
Stock 164 7.97 85.167 --- 
5 
Well 
water 2 6-10 205.3±1.3 6.70±0.09 0.054±0.037 99.9±0.0 
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Table C-1.  Passage of  Eosin Y aqueous sample over a 2-cm id chromatographic column packed with 
25cm of Octolig® in Batch 1 at a flow rate of 10 mL/min (50-mL aliquots were collected). 
 
Fraction No. TDS, ppm pH Concentration, 106M Absorbance 
1 3 7.78 0.681 0.049 
2 4 7.14 0.709 0.051 
3 12 6.46 0.695 0.05 
4 14 6.26 0.722 0.052 
5 14 6.13 0.695 0.05 
6 14 6.11 0.722 0.052 
7 14 6.26 0.709 0.051 
8 14 6.33 0.709 0.051 
9 14 6.31 0.709 0.051 
10 14 6.3 0.722 0.052 
Sample  9 6.27 11.031* 0.794* 
 
Average Concentration= 0.071 ×10-6M 
Standard Deviation= 0.001 
%Removal= 87.1±0.2 
* Sample was diluted 1:5. 
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Table C-2.  Passage of  Eosin Y aqueous sample with pH adjustion with NaOH over a 2-cm id 
chromatographic column packed with 25cm of Octolig® in Batch 1 at a flow rate of 10 mL/min (50-mL 
aliquots were collected). 
 
Fraction No. TDS, ppm pH Concentration, 106M Absorbance 
1 2 5.72 0.000 0.000 
2 4 5.65 0.000 0.000 
3 15 5.84 0.000 0.000 
4 20 5.87 0.000 0.000 
5 20 5.93 0.003 0.002 
6 20 5.95 0.000 0.000 
7 20 5.98 0.000 0.000 
8 20 6.07 0.000 0.000 
9 20 6.05 0.014 0.001 
10 20 6.11 0.000 0.000 
Sample  10 6.68 11.240* 0.809* 
 
Average Concentration= 0.001 ×10-6M 
Standard Deviation= 0.001 
%Removal= 100.0±0.2 
* Sample was diluted 1:5. 
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Table C-3.  Passage of  Eosin Y aqueous sample with pH adjustion with NaOH over a 2-cm id 
chromatographic column packed with 25cm of Octolig® in Batch 1 at a flow rate of 10 mL/min (50-mL 
aliquots were collected). 
 
Fraction No. TDS, ppm pH Concentration, 106M Absorbance 
1 2 5.73 0.102 0.007 
2 3 5.50 0.023 0.002 
3 10 5.78 0.085 0.006 
4 12 5.86 0.014 0.001 
5 13 5.92 0.086 0.006 
6 14 5.89 0.015 0.001 
7 13 6.10 0.085 0.006 
8 13 6.07 0.013 0.001 
9 13 6.02 0.015 0.001 
10 13 5.97 0.015 0.001 
Sample 10 6.72 17.256* 1.242* 
 
Average Concentration= 0.035 ×10-6M 
Standard Deviation= 0.035 
%Removal= 100.0±0.0 
* Sample was diluted 1:5. 
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Table C-4.  Passage of  Eosin Y aqueous sample with pH adjustion with NaOH over a 2-cm id 
chromatographic column packed with 25cm of Octolig® in Batch 2 at a flow rate of 10 mL/min (50-mL 
aliquots were collected). 
 
Fraction No. TDS, ppm pH Concentration, 106M Absorbance 
1 3 6.52 1.039 0.075 
2 4 6.28 0.852 0.061 
3 12 5.99 1.053 0.076 
4 15 5.98 0.852 0.061 
5 15 5.94 1.000 0.072 
6 15 5.89 0.856 0.062 
7 15 5.86 0.992 0.071 
8 15 5.89 0.863 0.062 
9 16 5.85 0.989 0.071 
10 15 5.87 0.860 0.062 
Sample 10 6.83 18.006* 1.296* 
 
Average Concentration= 0.927 ×10-6M 
Standard Deviation= 0.073 
%Removal= 99.0±0.1 
* Sample was diluted 1:5. 
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Table C-5.  Passage of  Eosin Y aqueous sample with pH adjustion with NaOH over a 2-cm id 
chromatographic column packed with 25cm of Octolig® in Batch 2 at a flow rate of 10 mL/min (50-mL 
aliquots were collected). 
 
Fraction No. TDS, ppm pH Concentration, 106M Absorbance 
1 3 5.57 0.056 0.004 
2 26 5.09 0.014 0.001 
3 172 6.02 0.097 0.007 
4 202 6.51 0.014 0.001 
5 205 6.65 0.097 0.007 
6 206 6.69 0.014 0.001 
7 206 6.73 0.097 0.007 
8 206 6.75 0.028 0.002 
9 206 6.79 0.097 0.007 
10 206 6.81 0.028 0.002 
Sample 164 7.97 17.003* 1.226* 
 
Average Concentration= 0.054 ×10-6M 
Standard Deviation= 0.041 
%Removal= 99.9±0.0 
* Sample was diluted 1:5. 
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Table D.  Passage of aqueous Erythrosine sample over a 2-cm id chromatographic column packed with 
Octolig® at a flow rate of 10 mL/min (50-mL aliquots were collected). 
 
Trial Matrix Batch Fraction TDS, ppm pH Concentration, 
106M 
%Removal 
Stock 30 7.48 59.662 --- 
1 DI water 1 4-10 31.1±0.8 6.71±0.06 0.642±0.027 98.9±0.0 
Stock 32 9.54 73.14 --- 
2 DI water 1 4-10 34.9±0.3 6.22±0.13 0.094±0.020 99.9±0.0 
Stock 28 8.66 78.753 --- 
3 DI water 2 4-10 31.9±0.3 6.13±0.10 0.046±0.027 99.9±0.0 
Stock 293 7.76 94.897 --- 
4 Tap water 2 4-10 352.7±7.5 7.45±0.08 0.122±0.019 99.9±0.0 
Stock 203 8.33 105.566 --- 
5 
Well 
water 2 4-10 199.9±1.2 8.42±0.06 1.504±0.070 98.6±0.1 
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Table D-1.  Passage of  Erythrosine aqueous sample over a 2-cm id chromatographic column packed with 
25cm of Octolig® in Batch 1 at a flow rate of 10 mL/min (50-mL aliquots were collected). 
 
Fraction No. TDS, ppm pH Concentration, 106M Absorbance %Removed 
1 12 6.74 0.014 0.001 100.0 
2 17 6.57 0.197 0.014 99.7 
3 31 6.70 0.604 0.043 99.0 
4 32 6.77 0.660 0.047 98.9 
5 32 6.79 0.632 0.045 98.9 
6 32 6.74 0.632 0.045 98.9 
7 31 6.69 0.632 0.045 98.9 
8 31 6.70 0.702 0.050 98.8 
9 30 6.65 0.618 0.044 99.0 
10 30 6.62 0.618 0.044 99.0 
Sample  30 7.48 5.9662* 0.425*  
 
Average Concentration= 0.642 ×10-6M 
Standard Deviation= 0.027 
%Removal= 98.9±0.0 
*Sample was diluted 1:10. 
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Table D-2.  Passage of  Erythrosine aqueous sample with pH adjustion with NaOH over a 2-cm id 
chromatographic column packed with 25cm of Octolig® in Batch 1 at a flow rate of 10 mL/min (50-mL 
aliquots were collected). 
 
Fraction No. TDS, ppm pH Concentration, 106M Absorbance %Removed 
1 3 6.84 0.056 0.004 99.9 
2 6 6.45 0.042 0.003 99.9 
3 27 5.97 0.126 0.009 99.8 
4 34 5.90 0.070 0.005 99.9 
5 35 6.23 0.112 0.008 99.8 
6 35 6.24 0.070 0.005 99.9 
7 35 6.27 0.112 0.008 99.8 
8 35 6.28 0.070 0.005 99.9 
9 35 6.30 0.112 0.008 99.8 
10 35 6.29 0.112 0.008 99.8 
Sample  32 9.54 7.314* 0.521*  
 
Average Concentration= 0.094 ×10-6M 
Standard Deviation= 0.023 
%Removal= 99.9±0.0 
*Sample was diluted 1:10. 
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Table D-3.  Passage of  Erythrosine aqueous sample with pH adjustion with NaOH over a 2-cm id 
chromatographic column packed with 25cm of Octolig® in Batch 2 at a flow rate of 10 mL/min (50-mL 
aliquots were collected). 
 
Fraction No. TDS, ppm pH Concentration, 106M Absorbance %Removed 
1 2 5.84 0.028 0.002 100.0 
2 5 5.53 0.014 0.001 100.0 
3 25 5.73 0.084 0.006 99.9 
4 31 5.93 0.042 0.003 99.9 
5 32 6.05 0.084 0.006 99.9 
6 32 6.14 0.042 0.003 99.9 
7 32 6.08 0.084 0.006 99.9 
8 32 6.21 0.042 0.003 99.9 
9 32 6.25 0.028 0.002 100.0 
10 32 6.22 0.000 0.000 100.0 
Sample  28 8.66 7.873* 0.56*  
 
Average Concentration= 0.046 ×10-6M 
Standard Deviation= 0.030 
%Removal= 99.9±0.0 
*Sample was diluted 1:10. 
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Table D-4.  Passage of  Erythrosine aqueous sample with pH adjustion with NaOH over a 2-cm id 
chromatographic column packed with 25cm of Octolig® in Batch 1 at a flow rate of 10 mL/min (50-mL 
aliquots were collected). 
 
Fraction No. TDS, ppm pH Concentration, 106M Absorbance %Removed 
1 4 7.15 0.042 0.003 100.0 
2 47 7.35 0.070 0.005 99.9 
3 265 7.38 0.168 0.012 99.8 
4 337 7.31 0.140 0.010 99.9 
5 345 7.32 0.154 0.011 99.8 
6 355 7.47 0.112 0.008 99.9 
7 359 7.49 0.126 0.009 99.9 
8 358 7.49 0.098 0.007 99.9 
9 358 7.5 0.126 0.009 99.9 
10 357 7.55 0.098 0.007 99.9 
Sample  293 7.76 9.490* 0.676*  
 
Average Concentration= 0.122 ×10-6M 
Standard Deviation= 0.021 
%Removal= 99.9±0.0 
*Sample was diluted 1:10. 
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Table D-5.  Passage of  Erythrosine aqueous sample with pH adjustion with NaOH over a 2-cm id 
chromatographic column packed with 25cm of Octolig® in Batch 2 at a flow rate of 10 mL/min (50-mL 
aliquots were collected). 
 
Fraction No. TDS, ppm pH Concentration, 106M Absorbance %Removed 
1 202 8.1 0.000 0.000 100.0 
2 195 8.27 0.281 0.020 99.7 
3 198 8.27 1.376 0.098 98.7 
4 198 8.31 1.600 0.114 98.5 
5 200 8.35 1.572 0.112 98.5 
6 200 8.42 1.572 0.112 98.5 
7 201 8.42 1.502 0.107 98.6 
8 201 8.47 1.446 0.103 98.6 
9 201 8.49 1.432 0.102 98.6 
10 198 8.49 1.404 0.100 98.7 
Sample  203 8.33 10.557* 0.752*  
 
Average Concentration= 1.504 ×10-6M 
Standard Deviation= 0.079 
%Removal= 98.6±0.1 
*Sample was diluted 1:10. 
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Table E. Passage of aqueous ZPS sample over a 2-cm id chromatographic column packed with Octolig® at 
a flow rate of 10 mL/min (50-mL aliquots were collected). 
 
Trial Matrix Batch Fraction TDS, ppm pH Concentration, 
106M 
%Removal 
Stock 16 6.99 126.294 --- 
1 DI water 1 4-10 23.3±3.7 6.79±0.16 3.860±0.159 96.9±0.1 
Stock 17 7.80 22.767 --- 
2 DI water 2 4-10 19.4±0.9 6.45±0.30 0.264±0.034 98.8±0.2 
Stock 183 7.54 4.081 --- 
3 Well water 2 4-10 234.1±3.9 7.09±0.16 0.000±0.000 100.0±0.0 
Stock 175 8.34 67.335 --- 
4 Well water 2 4-10 342.6±3.1 7.17±0.05 2.730±0.090 95.9±0.4 
Stock 16 6.48 57.219 --- 
5 DI water 2 4-10 18.3±0.8 6.43±0.05 1.424±0.145 97.5±0.0 
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Table E-1.  Passage of  ZPS aqueous sample over a 2-cm id chromatographic column packed with 25cm of 
Octolig® in Batch 1 at a flow rate of 10 mL/min (50-mL aliquots were collected). 
 
Fraction No. TDS, ppm pH Concentration, 106M Absorbance %Removed 
1 2 7.57 0.086 0.002 99.9 
2 9 7.36 0.601 0.014 99.5 
3 13 7.29 3.265 0.076 97.4 
4 15 7.16 4.038 0.094 96.8 
5 28 6.86 3.909 0.091 96.9 
6 26 6.80 4.081 0.095 96.8 
7 25 6.75 3.952 0.092 96.9 
8 24 6.70 3.694 0.086 97.1 
9 23 6.67 3.651 0.085 97.1 
10 22 6.62 3.694 0.086 97.1 
Sample  16 6.99 12.629* 0.294*  
 
Average Concentration= 3.860×10-6M 
Standard Deviation= 0.178 
%Removal= 96.9±0.1 
*Sample was diluted 1:10. 
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Table E-2.  Passage of  ZPS aqueous sample over a 2-cm id chromatographic column packed with 25cm of 
Octolig® in Batch 1 at a flow rate of 10 mL/min (50-mL aliquots were collected). 
 
Fraction No. TDS, ppm pH Concentration, 106M Absorbance %Removed 
1 5 7.19 0.000 0.000 100.0 
2 8 7.19 0.000 0.000 100.0 
3 17 7.13 0.129 0.003 99.4 
4 21 7.07 0.215 0.005 99.1 
5 20 6.76 0.258 0.006 98.9 
6 20 6.27 0.258 0.006 98.9 
7 19 6.29 0.258 0.006 98.9 
8 19 6.26 0.258 0.006 98.9 
9 19 6.24 0.258 0.006 98.9 
10 18 6.23 0.344 0.008 98.5 
Sample  17 7.80 277* 0.053*  
 
Average Concentration= 0.264×10-6M 
Standard Deviation= 0.039 
%Removal= 98.8±0.2 
*Sample was diluted 1:10. 
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Table E-3.  Passage of  ZPS aqueous sample over a 2-cm id chromatographic column packed with 25cm of 
Octolig® in Batch 1 at a flow rate of 10 mL/min (50-mL aliquots were collected). 
 
Fraction No. TDS, ppm pH Concentration, 106M Absorbance %Removed 
1 92 6.53 0.000 0.000 100.0 
2 103 6.58 0.000 0.000 100.0 
3 178 6.68 0.000 0.000 100.0 
4 225 6.90 0.000 0.000 100.0 
5 235 6.96 0.000 0.000 100.0 
6 236 6.99 0.000 0.000 100.0 
7 237 7.02 0.000 0.000 100.0 
8 238 7.11 0.000 0.000 100.0 
9 235 7.27 0.000 0.000 100.0 
10 233 7.41 0.000 0.000 100.0 
Sample  183 7.54 4.081* 0.095*  
 
Average Concentration= 0.000×10-6M 
Standard Deviation= 0.000 
%Removal= 100.0±0.0 
*Sample was diluted 1:10 
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Table E-4.  Passage of  ZPS aqueous sample over a 2-cm id chromatographic column packed with 25cm of 
Octolig® in Batch 1 at a flow rate of 10 mL/min (50-mL aliquots were collected). 
 
Fraction No. TDS, ppm pH Concentration, 106M Absorbance %Removed 
1 20 6.31 0.025 0.001 100.0 
2 134 6.00 1.812 0.042 97.3 
3 299 6.94 2.119 0.049 96.9 
4 335 7.06 2.636 0.061 96.1 
5 344 7.14 3.029 0.071 95.5 
6 345 7.16 2.948 0.069 95.6 
7 344 7.19 2.918 0.068 95.7 
8 344 7.20 2.711 0.063 96.0 
9 342 7.20 2.649 0.062 96.1 
10 344 7.21 2.223 0.052 96.7 
Sample  175 8.34 67.335 1.567  
 
Average Concentration= 2.730×10-6M 
Standard Deviation= 0.272 
%Removal= 95.9 ±0.4 
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Table E-5.  Passage of  ZPS aqueous sample over a 2-cm id chromatographic column packed with 25cm of 
Octolig® in Batch 1 at a flow rate of 10 mL/min (50-mL aliquots were collected). 
 
Fraction No. TDS, ppm pH Concentration, 106M Absorbance %Removed 
1 11 6.22 1.418 0.033 97.5 
2 11 6.21 1.418 0.033 97.5 
3 15 6.30 1.461 0.034 97.4 
4 20 6.41 1.461 0.034 97.4 
5 19 6.45 1.418 0.033 97.5 
6 18 6.51 1.418 0.033 97.5 
7 18 6.48 1.418 0.033 97.5 
8 18 6.45 1.418 0.033 97.5 
9 18 6.36 1.418 0.033 97.5 
10 17 6.35 1.418 0.033 97.5 
Sample  16 6.48 57.219 1.332  
 
Average Concentration= 1.424×10-6M 
Standard Deviation= 0.015 
%Removal= 97.5±0.0 
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Table F.  Passage of aqueous Lissamine Green B sample over a 3-cm id chromatographic column packed 
with Octolig® at a flow rate of 10 mL/min (50-mL aliquots were collected). 
 
Trial Matrix Batch Fraction TDS, ppm pH Concentration, 
106M 
%Removal 
Stock 9 6.27 9.087 --- 
1 DI water 1 4-10 8.1±0.3 6.20±0.10 0.017±0.005 99.8±0.1 
Stock 10 6.24 9.294 --- 
2 DI water 1 4-10 6.9±0.4 6.10±0.13 0.008±0.005 99.9±0.1 
Stock 169 8.09 7.636 --- 
3 
Well 
water 2 4-10 211±6 6.64±0.14 0.005±0.001 99.9±0.0 
Stock 174 7.92 7.542 --- 
4 
Well 
water 2 4-10 213±5 6.64±0.10 0.002±0.002 100±0.0 
Stock 175 7.88 0.74 --- 
5 
Well 
water 2 4-10 216±4 6.92±0.01 0.002±0.001 99.7±0.1 
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Table F-1.  Passage of  Lissamine Green B aqueous sample over a 3-cm id chromatographic column packed 
with 18cm of Octolig® in Batch 1 at a flow rate of 10 mL/min (50-mL aliquots were collected). 
 
Fraction No. TDS, ppm pH Concentration, 106M Absorbance %Removed 
1 13 6.77 0.033 0.003 99.6 
2 10 6.52 0.000 0.000 100.0 
3 8 6.42 0.011 0.001 99.9 
4 9 6.38 0.011 0.001 99.9 
5 8 6.30 0.022 0.002 99.8 
6 8 6.23 0.022 0.002 99.8 
7 8 6.16 0.011 0.001 99.9 
8 8 6.13 0.022 0.002 99.8 
9 8 6.11 0.022 0.002 99.8 
10 8 6.08 0.011 0.001 99.9 
Sample  9 6.27 9.087 0.835  
 
Average Concentration= 0.017×10-6M 
Standard Deviation= 0.006 
%Removal= 99.8±0.1 
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Table F-2.  Passage of  Lissamine Green B aqueous sample over a 3-cm id chromatographic column packed 
with 18cm of Octolig® in Batch 1 at a flow rate of 10 mL/min (50-mL aliquots were collected). 
 
Fration No. TDS, ppm pH Concentration, 106M Absorbance %Removed 
1 9 6.49 0.011 0.001 99.9 
2 8 6.38 0.000 0.000 100.0 
3 7 6.35 0.000 0.000 100.0 
4 7 6.31 0.011 0.001 99.9 
5 7 6.30 0.000 0.000 100.0 
6 7 6.14 0.011 0.001 99.9 
7 7 6.04 0.011 0.001 99.9 
8 7 6.00 0.011 0.001 99.9 
9 7 5.97 0.000 0.000 100.0 
10 6 5.96 0.011 0.001 99.9 
Sample  10 6.24 9.294 0.854  
 
Average Concentration= 0.008×10-6M 
Standard Deviation= 0.005 
%Removal= 99.9±0.1 
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Table F-3.  Passage of  Lissamine Green B aqueous sample over a 3-cm id chromatographic column packed 
with 18cm of Octolig® in Batch 2 at a flow rate of 10 mL/min (50-mL aliquots were collected). 
 
Fration No. TDS, ppm pH Concentration, 106M Absorbance %Removed 
1 4 7.79 0.005 0.000 99.9 
2 21 6.43 0.005 0.000 99.9 
3 145 6.15 0.004 0.000 99.9 
4 197 6.32 0.003 0.000 100.0 
5 210 6.57 0.003 0.000 100.0 
6 213 6.67 0.005 0.000 99.9 
7 213 6.71 0.005 0.000 99.9 
8 214 6.74 0.006 0.001 99.9 
9 213 6.67 0.004 0.000 100.0 
10 215 6.79 0.006 0.001 99.9 
Sample  169 8.09 7.636 0.702  
 
Average Concentration= 0.005×10-6M 
Standard Deviation= 0.001 
%Removal= 99.9±0.0 
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Table F-4.  Passage of  Lissamine Green B aqueous sample over a 3-cm id chromatographic column packed 
with 18cm of Octolig® in Batch 2 at a flow rate of 10 mL/min (50-mL aliquots were collected). 
 
Fration No. TDS, ppm pH Concentration, 106M Absorbance %Removed 
1 15 7.08 0.000 0.000 100.0 
2 32 6.51 0.000 0.000 100.0 
3 155 6.38 0.004 0.000 99.9 
4 201 6.45 0.001 0.000 100.0 
5 213 6.54 0.002 0.000 100.0 
6 215 6.63 0.000 0.000 100.0 
7 215 6.67 0.000 0.000 100.0 
8 216 6.70 0.005 0.000 99.9 
9 216 6.73 0.000 0.000 100.0 
10 216 6.75 0.004 0.000 100.0 
Sample  174  7.542 0.693  
 
Average Concentration= 0.002×10-6M 
Standard Deviation= 0.002 
%Removal= 100.0±0.0 
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Table F-5.  Passage of  Lissamine Green B aqueous sample over a 3-cm id chromatographic column packed 
with 18cm of Octolig® in Batch 2 at a flow rate of 10 mL/min (50-mL aliquots were collected). 
 
Fration No. TDS, ppm pH Concentration, 106M Absorbance %Removed 
1 11 6.36 0.002 0.00221 99.7 
2 24 6.28 0.003 0.00278 99.6 
3 151 6.41 0.002 0.00143 99.8 
4 207 6.91 0.002 0.00218 99.7 
5 216 6.90 0.001 0.00125 99.8 
6 218 6.91 0.003 0.00233 99.7 
7 218 6.92 0.001 0.00099 99.9 
8 218 6.92 0.003 0.00233 99.7 
9 218 6.92 0.001 0.00099 99.9 
10 219 6.95 0.002 0.00221 99.7 
Sample  175 7.88 0.074 0.06805  
 
Average Concentration= 0.002×10-6M 
Standard Deviation= 0.001 
%Removal= 99.7±0.1 
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Table G.  Passage of aqueous Amoxicillin sample over a 3-cm id chromatographic column packed with 
Octolig® at a flow rate of 10 mL/min (50-mL aliquots were collected). 
 
Trial Matrix Batch Fraction TDS, ppm pH Concentration, 
106M 
%Removal 
Stock 4 6.17 839.269 --- 
1 DI water 1 4-10 6±0 7.01±0.18 4.945±3.653 99.4±0.4 
Stock 3 6.19 1229.808 --- 
2 DI water 1 4-10 6±1 6.83±0.07 2.885±3.092 99.8±0.3 
Stock 5 5.97 741.346 --- 
3 DI water 2 4-10 2±1 5.59±0.10 17.170±9.594 98.8±0.6 
Stock 119 6.56 750.000 --- 
4 
Well 
water 2 4-10 176±14 6.48±0.06 11.676±0.012 99.2±0.4 
Stock 153 7.12 912.500 --- 
5 
Well 
water 2 4-10 193±24 6.72±0.06 57.418±22.258 96.9±1.2 
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Table G-1.  Passage of  Amoxicillin aqueous sample over a 3-cm id chromatographic column packed with 
18cm of Octolig® in Batch 1 at a flow rate of 10 mL/min (50-mL aliquots were collected). 
 
Fraction No. TDS, ppm pH Concentration, 106M Absorbance %Removed 
1 5 7.73 32.692 0.034 96.3 
2 5 7.59 13.462 0.014 98.5 
3 6 7.43 14.423 0.015 98.4 
4 7 7.32 1.923 0.002 99.8 
5 7 7.21 9.615 0.010 98.9 
6 6 7.08 1.923 0.002 99.8 
7 6 6.90 8.654 0.009 99.0 
8 6 6.95 1.923 0.002 99.8 
9 6 6.85 9.615 0.010 98.9 
10 6 6.74 0.962 0.001 99.9 
Sample  4 6.17 893.269 0.929  
 
Average Concentration= 4.945×10-6M 
Standard Deviation= 4.096 
%Removal= 99.4±0.5 
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Table G-2.  Passage of  Amoxicillin aqueous sample over a 3-cm id chromatographic column packed with 
18cm of Octolig® in Batch 1 at a flow rate of 10 mL/min (50-mL aliquots were collected). 
 
Fraction No. TDS, ppm pH Concentration, 106M Absorbance %Removed 
1 7 7.29 0.000 0.000 100.0 
2 6 7.22 0.000 0.000 100.0 
3 6 7.04 0.000 0.000 100.0 
4 7 6.94 0.000 0.000 100.0 
5 6 6.89 2.885 0.003 99.8 
6 6 6.84 0.000 0.000 100.0 
7 6 6.79 6.731 0.007 99.5 
8 6 6.87 0.962 0.001 99.9 
9 5 6.78 8.654 0.009 99.3 
10 5 6.73 0.962 0.001 99.9 
Sample  3 6.19 1229.808 1.279  
 
Average Concentration= 2.885×10-6M 
Standard Deviation= 3.467 
%Removal= 99.8±0.3 
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Table G-3.  Passage of  Amoxicillin aqueous sample over a 3-cm id chromatographic column packed with 
18cm of Octolig® in Batch 2 at a flow rate of 10 mL/min (50-mL aliquots were collected). 
 
Fraction No. TDS, ppm pH Concentration, 106M Absorbance %Removed 
1 2 5.99 0.000 0.000 100.0 
2 2 6.15 0.962 0.001 99.9 
3 2 5.93 10.577 0.011 99.3 
4 2 5.76 9.615 0.010 99.4 
5 2 5.69 9.615 0.010 99.4 
6 2 5.60 6.731 0.007 99.5 
7 2 5.58 16.346 0.017 98.9 
8 3 5.57 18.269 0.019 98.8 
9 3 5.48 21.154 0.022 98.6 
10 3 5.45 38.462 0.040 97.4 
Sample  5 5.97 741.346 0.771  
 
Average Concentration= 17.170×10-6M 
Standard Deviation= 10.756 
%Removal= 98.8±0.7 
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Table G-4.  Passage of  Amoxicillin aqueous sample over a 3-cm id chromatographic column packed with 
18cm of Octolig® in Batch 2 at a flow rate of 10 mL/min (50-mL aliquots were collected). 
 
Fraction No. TDS, ppm pH Concentration, 106M Absorbance %Removed 
1 8 7.09 0.000 0.000 100.0 
2 8 7.41 0.000 0.000 100.0 
3 59 6.68 0.000 0.000 100.0 
4 143 6.34 0.962 0.001 99.9 
5 171 6.45 17.308 0.018 98.8 
6 179 6.50 13.462 0.014 99.1 
7 181 6.50 10.577 0.011 99.3 
8 182 6.50 9.615 0.010 99.4 
9 184 6.51 13.462 0.014 99.1 
10 189 6.54 16.346 0.017 98.9 
Sample  119 6.56 750.000 0.780  
 
Average Concentration= 11.676×10-6M 
Standard Deviation= 4.887 
%Removal= 99.2±0.4 
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Table G-5.  Passage of  Amoxicillin aqueous sample over a 3-cm id chromatographic column packed with 
18cm of Octolig® in Batch 2 at a flow rate of 10 mL/min (50-mL aliquots were collected). 
 
Fraction No. TDS, ppm pH Concentration, 106M Absorbance %Removed 
1 2 6.52 19.231 0.020 98.9 
2 4 7.07 37.500 0.039 97.9 
3 71 6.87 47.115 0.049 97.4 
4 133 6.72 44.231 0.046 97.6 
5 188 6.71 41.346 0.043 97.7 
6 203 6.70 36.538 0.038 98.0 
7 206 6.61 44.231 0.046 97.6 
8 206 6.74 53.846 0.056 97.0 
9 206 6.77 75.962 0.079 95.8 
10 207 6.81 105.769 0.110 94.2 
Sample  153 7.12 912.500 0.949  
 
Average Concentration= 57.418×10-6M 
Standard Deviation= 22.258 
%Removal= 96.9±1.4 
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Appendices B: Spectra for model compounds 
 
FigA-1. Spectra for Methylene blue Trial 1 aqueous fractions and sample. 
 
FigA-2. Spectra for Methylene blue Trial 2 aqueous fractions and sample. 
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FigA-3. Spectra for Methylene blue Trial 3 aqueous fractions and sample. 
 
Fig
B-1. Spectra for Rose Bengal Trial 1 aqueous fractions and sample.	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FigB-2. Spectra for Rose Bengal Trial 2 aqueous fractions and sample. 	  
 
FigB-3. Spectra for Rose Bengal Trial 3 aqueous fractions and sample. 
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FigB-4. Spectra for Rose Bengal Trial 4 aqueous fractions and sample. 
 
 
FigB-5. Spectra for Rose Bengal Trial 5 aqueous fractions and sample.	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FigC-1. Spectra for Eosin Y Trial 1 aqueous fractions and sample. 	  
	  
FigC-2. Spectra for Eosin Y Trial 2 aqueous fractions and sample. 	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Fig
C-3. Spectra for Eosin Y Trial 3 aqueous fractions and sample. 
 
 
FigC-4. Spectra for Eosin Y Trial 4 aqueous fractions and sample. 
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FigC-5. Spectra for Eosin Y Trial 5 aqueous fractions and sample.	  	  
	  
FigD-1. Spectra for Erythrosine Trial 1 aqueous fractions and sample 
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FigD-2. Spectra for Erythrosine Trial 2 aqueous fractions and sample. 
 
 
FigD-3. Spectra for Erythrosine Trial 3 aqueous fractions and sample. 	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FigD-4. Spectra for Erythrosine Trial 4 aqueous fractions and sample. 	  
	  
FigD-5. Spectra for Erythrosine Trial 5 aqueous fractions and sample.	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FigE-1. Spectra for ZPS Trial 1 aqueous fractions and sample. 	  
	  
FigE-2. Spectra for ZPS Trial 2 aqueous fractions and sample. 	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FigE-3. Spectra for ZPS Trial 3 aqueous fractions and sample. 
 
 
FigE-4. Spectra for ZPS Trial 4 aqueous fractions and sample. 
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FigE-5. Spectra for ZPS Trial 5 aqueous fractions and sample. 
 
 
FigF-1. Spectra for Lissamine Green B Trial 1 aqueous fractions and sample. 
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FigF-2. Spectra for Lissamine Green B Trial 2 aqueous fractions and sample. 
 
 
FigF-3. Spectra for Lissamine Green B Trial 3 aqueous fractions and sample. 
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FigF-4. Spectra for Lissamine Green B Trial 4 aqueous fractions and sample. 
 
 
FigF-5. Spectra for Lissamine Green B Trial 5 aqueous fractions and sample. 
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FigG-1. Spectra for Amoxicillin Trial 1 aqueous fractions and sample. 
 
 
FigG-2. Spectra for Amoxicillin Trial 2 aqueous fractions and sample. 
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FigG-3. Spectra for Amoxicillin Trial 3 aqueous fractions and sample. 
 
 
FigG-4. Spectra for Amoxicillin Trial 4 aqueous fractions and sample. 
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FigG-5. Spectra for Amoxicillin Trial 5 aqueous fractions and sample. 
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